FluoGuide A/S approved for listing on Spotlight

FluoGuide A/S, a Danish based company improving precision in surgery, has today been approved for listing on Spotlight Stock Market. FluoGuide will raise capital through an issue of units to reach clinical proof-of-concept for its first product – FG001 – which is lighting up cancer during surgery. The subscription starts on Monday 1st April 2019. The prospectus is available at Spotlight Stock Market (www.spotlightstockmarket.com) and FluoGuide (www.fluoguide.com). Teaser and subscription form will be published on the webpages mentioned above at the start of the subscription period.

FluoGuide – intelligent surgical targetingFluoGuide A/S develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reduce costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. To begin with, the Company focus on glioblastoma (brain tumor). Common practice causes local cancer tissue to be left behind in up to 50 % of patients undergoing surgery with the intention to completely remove the cancer. In a recently performed non-human preclinical study on eight subjects, additional metastasis was found in four of the eight subjects using FG001 and fluorescent light. This means that in half of the subjects (50 %) traditional white light surgery overlooked cancer tissue that could be seen and removed with FG001. These results demonstrate the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival.

I am thrilled by the huge interest we have received for our innovative solution to light up cancer during surgery and look forward to bring this product to clinical use for the benefit of patients together with an extraordinary team”, comments Morten Albrechtsen, CEO of FluoGuide

Issue of unitsIn order to add capital, FluoGuide has decided to raise initially approximately DKK 15.9 million before issue costs through an issue of units, prior to the listing at Spotlight Stock Market. The proceeds that FluoGuide is provided through the initial issue of units are primarily intended to finance the proof-of-concept Phase I/IIa study with FG001 as well as recruitment of a basic organization and EMA and FDA consultation. The Board of Directors assesses that the proceeds will be sufficient to finalize proof-of-concept for FG001.

Listing at Spotlight Stock MarketFluoGuide has been approved for listing at Spotlight Stock Market. The approval is given under the condition that the company raises it’s estimated minimum of DKK 12.8 million and that the company obtains a sufficient number of shareholders. The first day of trading on Spotlight Stock Market is planned to be the 7th of May 2019.

The offer in summary:

 Subscription price in the new share issue: DKK 14.85 per unit. One (1) unit consists of three (3) shares and one (1) consideration free warrant of series TO 1. The price per share is thus DKK 4.95 

Subsciption post: The minimum subscription is 250 units, corresponding to DKK 3,737.50. 

Subscription period: April 1st – April 15th, 2019. 

New share issue volume: The offering comprises a total of 3,224,274 shares and 1,074,758 warrants of series TO 1, initially corresponding to DKK 15,960,156.30 at the most. The minimum limit to implement the issue of units is 864,648 units, corresponding to DKK 12,840,022.80. 

Valuation pre-money: Approximately DKK 19.8 million. 

Expected first day of trading: May 7th under the ticker name FLUO

For more information, please contact:

Oskar Wollert

Head of Listing, Spotlight Stock Market

+46 8 511 68 008



Documents & Links